Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-1-23
pubmed:abstractText
We treated nine patients (10 episodes) with meningitis caused by Streptococcus pneumoniae isolates with decreased susceptibilities to broad-spectrum cephalosporins with high doses of cefotaxime (300 mg/kg of body weight per day; maximum dose, 24 g/day). Early adjunctive therapy with dexamethasone was also administered. Cefotaxime MICs were 0.5 (three episodes), 1 (five episodes), and 2 (two episodes) micrograms/ml, and MBCs ranged from 1 to 4 micrograms/ml. Therapy was well tolerated, and all patients experienced prompt clinical improvement. One patient died 8 days after the end of therapy, the central nervous system infection had already been cured, and the remaining patients recovered without relapses.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1452492, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1523079, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1572984, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1617079, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1749702, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-1810180, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-2041676, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-2183667, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-2626294, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-3364443, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-39493, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-6281285, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-7619994, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-7870156, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8028618, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8075268, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8092832, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8161625, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8215275, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8315005, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8451095, http://linkedlifedata.com/resource/pubmed/commentcorrection/8787909-8460930
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
218-20
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.
pubmed:affiliation
Infectious Diseases Service, University of Barcelona, Spain.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't